3 days ago · Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna …

3 days ago · Goldman forecast RSV vaccine revenue of $1.5 billion, which is at the lowest end of the $1.5 billion to $2.5 billion range produced by Moderna. The Goldman team also says …

3 days ago · Moderna’s guidance for fiscal year 2025 (FY2%) revenue from the respiratory vaccine business is between $1.5 billion and $2.5 billion, aligning with Goldman’s estimate of …

3 days ago · Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions …

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its …

3 days ago · Analyst Salveen Richter downgraded shares of the biotech company from neutral to buy and significantly lowered her price target.

3 days ago · mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier …

4 days ago · Moderna (NASDAQ:MRNA - Get Free Report) had its price objective lowered by stock analysts at The Goldman Sachs Group from $112.00 to $99.00 in a research note …

Moderna stock falls after Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed price target to $51 from $99 Wednesday.

Moderna stock was losing ground as investors appeared increasingly doubtful its vaccine sales will be able to lift the beaten-down share price. Goldman Sachs cut its recommendation on the …